… drugs for AD is the blood–brain barrier (BBB). A combination of nanotechnology with fluorinated
molecules … conducted on fluorine-containing compounds and fluorinated nanoparticles (…

… of cancers, infectious diseases, CNS disorders and some other diseases. It … imaging agent,
containing 18 F isotope of fluorine has been extensively utilized in developing PET imaging …

… fluorine-18 and proved to be PET imaging agents for the diagnosis of cancer (101, 102). The
importance of molecular imaging … is the high brain enzyme density (V T ) with scan duration …

… living brain, it suggests the use of fluorinated benzimidazole … -NML as a tau PET imaging
agent was evaluated (Figure 6). … , might be useful tools for AD drug development. In addition, …

… To achieve the functionalization of the CPBs, like incorporation of imaging contrast agents
or drugs, we converted the epoxy side groups in the PGMA block to azido groups and …

… was approved by the Food & Drug Administration (FDA) to image Tau pathology in patients
… that the PET images reflect the known NFTs distribution in an AD brain. However, this probe …

… to synthesize various small drug molecules. The fluorophilic … molecule (6) was developed
as TrkB based brain imaging … as hCA mediated PET imaging agent under hypoxia conditions…

… However, the lack of suitable imaging agents severely … fluorinated drugs on the market, 10
PFTB-bioactive agents are … between PFTB-agents and brain tissue severely shortened the T 2 …

… Meanwhile, direct effects of siponimodon the central nervous system were uncovered.
This drug can cross the blood–brain barrier, affecting neurobiological processes through …

… (PET) imaging of the GABAergic system in the CNS has been … using [ 18 F]fluoride, and
subsequent PET imaging in mice … need for PET imaging agents with molecular targets in the …